# A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

> **NCT05334823** · PHASE2 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 100 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Relapsed Pediatric ALL
- Refractory Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** pCAR-19B cells

## Key facts

- **NCT ID:** NCT05334823
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-26
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-07-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05334823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05334823, "A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05334823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*